Cardio Diagnostics
Get Started
Hero Background

Epi+Gen CHD™

Three-year Coronary Heart Disease Event Risk Assessment

What is Epi+Gen CHD™?

Epi+Gen CHD™ is a clinical blood test, available by prescription only, that assesses the three-year risk of a coronary heart disease event, including a heart attack and sudden death. It evaluates a targeted panel of three epigenetic and five genetic biomarkers. By applying artificial intelligence, this test predicts with high sensitivity a patient's risk of having a coronary heart disease event within the next three years.

Epi+Gen CHD™ allows providers to sensitively assess risk of a coronary heart disease event regardless of the presence and severity of traditional risk factors. With re-testing, the DNA methylation biomarkers of Epi+Gen CHD™ have been demonstrated to change in response to intervention. This test is non-invasive and does not require fasting.

Epi+Gen CHD™
Rx Only   FSA/HSA Eligible

2x

more sensitive than conventional risk calculators

Non-Invasive, No Radiation, No Fasting

Understanding the Epi+Gen CHD™ Risk Score

Epi+Gen CHD™ delivers a precise risk score informed by the patient's molecular profile.

Low

Borderline

7.1%

Intermediate

High

This example illustrates the Epi+Gen CHD™ clinical report, showing a patient's three-year risk of a coronary heart disease event as borderline at 7.1%. The report also compares the patient's risk to peers of the same sex and age, while providing a detailed explanation of the common drivers of heart disease.

Epi+Gen CHD™ Is Intended for Patients Who:

Rx Only   FSA/HSA Eligible

Are between 35 to 75 years old

Are between 35 to 75 years old

Have not been diagnosed with heart disease

Have not been diagnosed with heart disease

Have not had an abnormal stress test

Have not had an abnormal stress test

Have not experienced a heart attack or cardiac surgery

Have not experienced a heart attack or cardiac surgery

Have not had a bone marrow transplant

Have not had a bone marrow transplant

Do not suffer from angina (chest pain), especially with exertion

No history of angina (chest pain), especially with exertion

No Radiation  ●  No Fasting  ●  Compatible with Telemedicine

Quantify Heart Attack Risk at the Molecular Level With Epi+Gen CHD™

Get Started
  1. Dogan, M. V., S. Knight, T. K. Dogan, K. U. Knowlton, and R. Philibert. "External Validation of Integrated Genetic-Epigenetic Biomarkers for Predicting Incident Coronary Heart Disease." Epigenomics 13, no. 14 (2021): 1137–1152. https://doi.org/10.2217/epi-2021-0123

Who We Serve

PatientsProvidersEmployers

Our Solutions

OverviewEpi+Gen CHD™PrecisionCHD™HeartRisk™CardioInnovate360™

Company

About UsAbout CVDCareersTechnologyResourcesContact Us

Investors

Stock InformationSEC FilingsPress ReleasesPresentationsEmail SubscriptionCorporate GovernanceContact Investor Relations
Contact Us

2026 Cardio Diagnostics, Inc.

Privacy PolicyTerms of UseHIPAA Notice

The Cardio Diagnostics clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing. The Epi+Gen CHD™ and PrecisionCHD™ tests were developed, and their performance characteristics were determined by Cardio Diagnostics. These tests should be ordered by a licensed healthcare provider, and test results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms, and other relevant clinical information. These tests are intended for clinical purposes and have not been cleared or approved by the U.S. Food and Drug Administration (FDA).

For the Epi+Gen CHD™ test, a lower risk result does not eliminate the possibility of a coronary heart disease event occurring or that coronary heart disease is present, and a higher risk result does not imply a diagnosis of coronary heart disease or that a coronary heart disease event will occur. For the PrecisionCHD™ test, a "Signal Detected" result is not a diagnosis of coronary heart disease, and a "Signal Not Detected" result does not eliminate the possibility that coronary heart disease is present or could occur in the future. False positive and false negative test results do occur. Rx only.

In addition to a federal CLIA license, the Cardio Diagnostics clinical laboratory holds active state clinical laboratory licenses in California, Maryland, Pennsylvania, and Rhode Island. The laboratory is not currently licensed to process patient samples originating from the state of New York.